Physician profile
Brian A Pollock
NPI 1558319780
$2,199.83
in general payments reported to CMS, 2019-2025
21 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.49 · 2020: $20.91 · 2021: $65.02 · 2022: $27.55 · 2023: $175 · 2024: $672 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308.80 | 2024-2025 | |
| Novo Nordisk INC | $244.68 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $203.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.48 | 2023-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.72 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $156.48 | 2024-2025 | Nucala, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $152.25 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $114.08 | 2025 | |
| Lilly USA, LLC | $95.25 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Organogenesis INC. | $93.09 | 2023 | Puraply |
| Exact Sciences Corporation | $91.19 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $78.91 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Astellas Pharma US INC | $72.21 | 2023-2025 | Veozah |
| Amgen INC. | $44.51 | 2021-2025 | Otezla, Repatha |
| Lundbeck LLC | $40.74 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $36.95 | 2025 | |
| Merck Sharp & Dohme LLC | $33.98 | 2025 | Capvaxive, Gardasil 9 |
| Daiichi Sankyo INC. | $20.91 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.15 | 2019 | |
| Smith+Nephew, INC. | $15.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.